Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

This study has been completed.
Sponsor:
Collaborators:
University of Hawaii
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT01386970
First received: June 28, 2011
Last updated: December 11, 2012
Last verified: December 2012

June 28, 2011
December 11, 2012
May 2005
July 2008   (final data collection date for primary outcome measure)
To compare zidovudine (ZDV)- and lamivudine (3TC)-triphosphate concentrations in women versus men. [ Time Frame: 12 days ] [ Designated as safety issue: No ]
1st dose and day 12 dose compared after 12 days
To compare zidovudine (ZDV)- and lamivudine (3TC)-triphosphate concentrations in women versus men. [ Time Frame: 12 days ] [ Designated as safety issue: No ]
1st dose and day 12 dose compatred after 12 days
Complete list of historical versions of study NCT01386970 on ClinicalTrials.gov Archive Site
  • Change in mitochondrial DNA before and after blood analysis [ Time Frame: day 12 (HIV negative) up to 2 years (HIV-infected) ] [ Designated as safety issue: Yes ]
    To investigate relationships between ZDV- and 3TC-triphosphate concentrations and changes in mitochondrial DNA
  • To investigate relationships between ZDV- and 3TC-triphosphate concentrations and the incidence of clinical side effects. [ Time Frame: day 12 (HIV-negative) various longer duration in times (HIV-infected) ] [ Designated as safety issue: Yes ]
  • Drug levels compared between HIV negative and HIV infected subject [ Time Frame: 1st dose and day 12 dose ] [ Designated as safety issue: No ]
    To compare ZDV- and 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.
Same as current
genetic associations with ZDV and 3TC disposition [ Time Frame: study time frame ] [ Designated as safety issue: No ]
Variability in genes encoding proteins influencing the disposition of ZDV and 3TC will be correlated with ZDV and 3TC disposition.
Not Provided
 
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Sex and Disease Dependent Nucleoside Analog Toxicity

This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection. Additionally, markers of side effects were correlated with blood levels of the drugs. The hypothesis was that women and those with HIV would have higher drug levels, as well as markers of side effects.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
HIV
Drug: zidovudine 300mg and lamivudine 150mg as Combivir
twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
  • Active Comparator: HIV-negative
    This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
    Intervention: Drug: zidovudine 300mg and lamivudine 150mg as Combivir
  • Active Comparator: HIV-infected
    This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
    Intervention: Drug: zidovudine 300mg and lamivudine 150mg as Combivir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
51
July 2010
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented physician-diagnosed HIV-infection (HIV+ antibody or plasma HIV-RNA+); HIV-negative volunteers must have a negative HIV-ELISA.
  • Age 18 to 55 years;
  • Either antiretroviral naïve, or no HIV-therapy in the preceding 6 months;
  • Planned antiretroviral regimen includes standard doses of ZDV plus 3TC as part of the antiretroviral regimen. Once- or twice-daily 3TC will be allowed.

Exclusion Criteria:

  • Any medical condition that in the opinion of the investigators would jeopardize the intent of the study.
  • In the opinion of the investigator, any concomitant immunomodulatory medications, chemotherapeutic agents, investigational drugs, and alternative therapies, including, glucocorticoids, recombinant growth factors or cytokines (e.g. Granulocyte-macrophage colony-stimulating factor, Granulocyte colony-stimulating factor, interferon-alpha or gamma, human growth hormone, etc), ribavirin, birth-control pills, and sex hormones that could interfere with the cellular pharmacology of the study medications;
  • Concomitant medications that interfere with renal drug clearances including, tenofovir, adefovir, cidofovir, ganciclovir, probenecid, or any similarly problematic medication in the opinion of the investigators;
  • Concomitant warfarin or daily aspirin (to prevent excess bleeding from biopsy).
  • Pregnancy or a plan to become pregnant, or menopause;
  • Any > or = grade II abnormality in hemoglobin, absolute neutrophil count, routine liver function tests, serum creatinine, or other organ function abnormalities.
  • Any medical or personal condition that, in the judgment of the investigators, may influence the subject's ability to comply with study conditions, such as active mental illnesses, or plans to leave the geographical area.
  • Inability to give informed consent.
  • Triple nucleoside analog reverse transcriptase regimens.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01386970
04-1101, R01AI064029
Yes
University of Colorado, Denver
University of Colorado, Denver
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Hawaii
Principal Investigator: Peter L. Anderson, PharmD University of Colorado Denver and Health Sciences Center
University of Colorado, Denver
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP